JPMorgan analyst Cory Kasimov maintains Overweight on Clovis Oncology (NASDAQ: CLVS).The analyst says he was encouraged by the company's announcement ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE